{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,28]],"date-time":"2026-07-28T06:00:12Z","timestamp":1785218412282,"version":"3.55.0"},"reference-count":51,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2026,7,28]],"date-time":"2026-07-28T00:00:00Z","timestamp":1785196800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Endocrinol."],"abstract":"<jats:sec>\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>Semaglutide has shown significant efficacy in several clinical trials for the treatment of obesity. However, real-world data on early weight loss and metabolic response in obesity without diabetes cohort are still limited, particularly with respect to individual patient factors. This study aims to evaluate the real-world effectiveness of semaglutide on anthropometric and metabolic parameters in an obesity cohort, including weight loss (kg and percent) and the percentage of participants achieving the 5%, 10% and 15% weight loss targets at mean 3-month, 6-month and 12-month follow-up. In addition, an assessment of safety and reasons for discontinuation, and sub-analyses of anthropometric outcomes by prior liraglutide exposure, sex, and BMI categories will be included.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>In this retrospective study, data were collected from adults with overweight\/obesity without diabetes treated with weekly subcutaneous semaglutide for at least 3 months and analyzed at 2-4 (T1), 5-8 (T2), and 9-15 (T3) months of follow-up.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>\n                      Among 248 patients (55.0 years, 34.8 kg\/m\n                      <jats:sup>2<\/jats:sup>\n                      , 77.5% female), only 10.4% and 5.7%, respectively, discontinued due to non-severe gastrointestinal adverse events or cost. Significant weight loss (WL), %WL goal attainment, and improvements in adiposity and metabolic outcomes, including hepatic steatosis, fibrosis, and visceral adiposity indices, were observed at all follow-up visits. Early metabolic improvements occurred regardless of %WL\u22655 target. Reduced early anthropometric response in switchers (24%) vs. naive subjects with similar one-year outcomes and no significant differences by sex or baseline BMI category were observed.\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusions<\/jats:title>\n                    <jats:p>These results confirm semaglutide\u2019s effectiveness on cardiometabolic risk in real-world obesity management, with a safety profile and early metabolic effects independent of weight loss. The reduced early response in switchers and at low doses highlights the importance of dose optimization to prevent suboptimal initial outcomes after switching. The lack of differences by sex and BMI category supports further studies stratifying patients by age and metabolic risk rather than BMI alone. Low persistence highlights the need for structured, patient-centered support to improve adherence and a better understanding of the drivers of discontinuation.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.3389\/fendo.2026.1819337","type":"journal-article","created":{"date-parts":[[2026,7,28]],"date-time":"2026-07-28T05:35:22Z","timestamp":1785216922000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":0,"title":["Real-world semaglutide in obesity cohort: effectiveness, safety and persistence across sex, BMI, and prior GLP-1RA treatment"],"prefix":"10.3389","volume":"17","author":[{"given":"Ilaria","family":"Milani","sequence":"first","affiliation":[{"name":"Department of Medico-Surgical Sciences and Biotechnologies, Faculty of Pharmacy and Medicine, University of Rome La Sapienza","place":["Lazio, Italy"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Maria Eugenia","family":"Parrotta","sequence":"additional","affiliation":[{"name":"Department of Systems Medicine, University of Rome Tor Vergata","place":["Rome, Italy"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marianna","family":"Chinucci","sequence":"additional","affiliation":[{"name":"Department of Medico-Surgical Sciences and Biotechnologies, Faculty of Pharmacy and Medicine, University of Rome La Sapienza","place":["Lazio, Italy"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Emanuele","family":"Franz\u00f2","sequence":"additional","affiliation":[{"name":"Department of Medico-Surgical Sciences and Biotechnologies, Faculty of Pharmacy and Medicine, University of Rome La Sapienza","place":["Lazio, Italy"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Elena","family":"Gintoli","sequence":"additional","affiliation":[{"name":"Obesity Medical Center, University Hospital Policlinico Tor Vergata","place":["Rome, Italy"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Francesco","family":"Franco","sequence":"additional","affiliation":[{"name":"Obesity Medical Center, University Hospital Policlinico Tor Vergata","place":["Rome, Italy"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Paolo","family":"Sbraccia","sequence":"additional","affiliation":[{"name":"Department of Systems Medicine, University of Rome Tor Vergata","place":["Rome, Italy"]},{"name":"Obesity Medical Center, University Hospital Policlinico Tor Vergata","place":["Rome, Italy"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Valeria","family":"Guglielmi","sequence":"additional","affiliation":[{"name":"Department of Systems Medicine, University of Rome Tor Vergata","place":["Rome, Italy"]},{"name":"Obesity Medical Center, University Hospital Policlinico Tor Vergata","place":["Rome, Italy"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Danila","family":"Capoccia","sequence":"additional","affiliation":[{"name":"Department of Medico-Surgical Sciences and Biotechnologies, Faculty of Pharmacy and Medicine, University of Rome La Sapienza","place":["Lazio, Italy"]}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1965","published-online":{"date-parts":[[2026,7,28]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","DOI":"10.3390\/medicines12030019","article-title":"Obesity: clinical impact, pathophysiology, complications, and modern innovations in therapeutic strategies","volume":"12","author":"Ullah","year":"2025","journal-title":"Medicines"},{"key":"B2","doi-asserted-by":"publisher","DOI":"10.1016\/j.obmed.2025.100588","article-title":"Obesity-driven hunger: from pathophysiology to intervention","volume":"54","author":"Azemi","year":"2025","journal-title":"Obes Med"},{"key":"B3","doi-asserted-by":"publisher","DOI":"10.1186\/s43556-025-00264-9","article-title":"Obesity: pathophysiology and therapeutic interventions","volume":"6","author":"Kong","year":"2025","journal-title":"Mol BioMed"},{"key":"B4","doi-asserted-by":"publisher","DOI":"10.1007\/s13679-024-00602-y","article-title":"Long-term efficacy and safety of nutritional and pharmacological strategies for obesity","volume":"14","author":"Barrea","year":"2025","journal-title":"Curr Obes Rep"},{"key":"B5","doi-asserted-by":"publisher","DOI":"10.1007\/s13679-023-00502-7","article-title":"Beyond weight loss: added benefits could guide the choice of anti-obesity medications","volume":"12","author":"Guglielmi","year":"2023","journal-title":"Curr Obes Rep"},{"key":"B6","doi-asserted-by":"publisher","DOI":"10.3390\/ph18071058","article-title":"Weight loss effects of once-weekly semaglutide 2.4 mg in adults with and without type 2 diabetes: a systematic review and meta-analysis","volume":"18","author":"Hong","year":"2025","journal-title":"Pharm (Basel)"},{"key":"B7","doi-asserted-by":"publisher","DOI":"10.1093\/obendo\/wjaf011","article-title":"Semaglutide in a real-world outpatient setting: discontinuation patterns and weight maintenance","volume":"1","author":"Brufani","year":"2025","journal-title":"Obes Endocrinol"},{"key":"B8","doi-asserted-by":"publisher","DOI":"10.3390\/ph18030399","article-title":"Semaglutide as a GLP-1 agonist: a breakthrough in obesity treatment","volume":"18","author":"Salvador","year":"2025","journal-title":"Pharmaceuticals"},{"key":"B9","doi-asserted-by":"publisher","DOI":"10.3390\/medsci13040265","article-title":"Semaglutide from bench to bedside: the experimental journey towards a transformative therapy for diabetes, obesity and metabolic liver disorders","volume":"13","author":"Weiskirchen","year":"2025","journal-title":"Med Sci (Basel)"},{"key":"B10","doi-asserted-by":"publisher","DOI":"10.2337\/dc25-S002","article-title":"2. diagnosis and classification of diabetes: standards of care in diabetes\u20142025","volume":"48","year":"2024","journal-title":"Diabetes Care"},{"key":"B11","doi-asserted-by":"publisher","first-page":"492","DOI":"10.1016\/j.jhep.2024.04.031","article-title":"EASL\u2013EASD\u2013EASO clinical practice guidelines on the management of metabolic dysfunction-associated steatotic liver disease (MASLD)","volume":"81","author":"Tacke","year":"2024","journal-title":"J Hepatol"},{"key":"B12","doi-asserted-by":"publisher","DOI":"10.2337\/dc09-1825","article-title":"Visceral adiposity index","volume":"33","author":"Amato","year":"2010","journal-title":"Diabetes Care"},{"key":"B13","doi-asserted-by":"publisher","first-page":"989","DOI":"10.1056\/NEJMoa2032183","article-title":"Once-weekly semaglutide in adults with overweight or obesity","volume":"384","author":"Wilding","year":"2021","journal-title":"N Engl J Med"},{"key":"B14","doi-asserted-by":"publisher","DOI":"10.1038\/s41591-022-02026-4","article-title":"Two-year effects of semaglutide in adults with overweight or obesity: the STEP 5 trial","volume":"28","author":"Garvey","year":"2022","journal-title":"Nat Med"},{"key":"B15","doi-asserted-by":"publisher","DOI":"10.1001\/jamanetworkopen.2022.31982","article-title":"Weight loss outcomes associated with semaglutide treatment for patients with overweight or obesity","volume":"5","author":"Ghusn","year":"2022","journal-title":"JAMA Netw Open"},{"key":"B16","doi-asserted-by":"publisher","DOI":"10.7759\/cureus.59558","article-title":"A real-world study of the effectiveness and safety of semaglutide for weight loss","volume":"16","author":"Tzoulis","year":"2024","journal-title":"Cureus"},{"key":"B17","doi-asserted-by":"publisher","first-page":"66","DOI":"10.1111\/dom.16364","article-title":"Real-world evidence on the utilization, clinical and comparative effectiveness, and adverse effects of newer GLP-1RA-based weight-loss therapies","volume":"27","author":"Thomsen","year":"2025","journal-title":"Diabetes Obes Metab"},{"key":"B18","doi-asserted-by":"publisher","DOI":"10.1111\/dom.15523","article-title":"The association between previous use of anti-obesity medication and semaglutide weight loss outcomes","volume":"26","author":"Ghusn","year":"2024","journal-title":"Diabetes Obes Metab"},{"key":"B19","doi-asserted-by":"publisher","first-page":"4993","DOI":"10.1007\/s12325-025-03320-6","article-title":"Semaglutide 2.4 mg clinical outcomes in patients with obesity or overweight: a real-world retrospective comparative cohort study","volume":"42","author":"Ruseva","year":"2025","journal-title":"Adv Ther"},{"key":"B20","first-page":"6200","article-title":"Real\u2010world titration, persistence & weight loss of semaglutide and tirzepatide in an academic obesity clinic","volume":"27","author":"Samuels","year":""},{"key":"B21","doi-asserted-by":"publisher","DOI":"10.2337\/dc24-1082","article-title":"Real-world use of semaglutide for weight management: patient characteristics and dose titration\u2014a Danish cohort study","volume":"47","author":"Ladebo","year":"2024","journal-title":"Diabetes Care"},{"key":"B22","doi-asserted-by":"publisher","first-page":"18","DOI":"10.1111\/dom.14863","article-title":"Semaglutide for the treatment of overweight and obesity: a review","volume":"25","author":"Bergmann","year":"2023","journal-title":"Diabetes Obes Metab"},{"key":"B23","doi-asserted-by":"publisher","DOI":"10.1016\/j.diabet.2019.10.001","article-title":"Efficacy of semaglutide versus liraglutide in clinical practice","volume":"46","author":"Goncalves","year":"2020","journal-title":"Diabetes Metab"},{"key":"B24","doi-asserted-by":"publisher","DOI":"10.3389\/fendo.2022.892702","article-title":"Effectiveness and tolerability of once-weekly GLP-1 receptor agonists in clinical practice: a focus on switching between once-weekly molecules in type 2 diabetes","volume":"13","author":"Di Dalmazi","year":"2022","journal-title":"Front Endocrinol"},{"key":"B25","doi-asserted-by":"publisher","DOI":"10.1007\/s13300-021-01010-4","article-title":"Outcomes in GLP-1 RA-experienced patients switching to once-weekly semaglutide in a real-world setting: the retrospective, observational EXPERT study","volume":"12","author":"Lingvay","year":"2021","journal-title":"Diabetes Ther"},{"key":"B26","doi-asserted-by":"publisher","DOI":"10.1016\/j.xcrm.2025.102308","article-title":"Can muscle avert GLP1R weight plateau and regain","volume":"6","author":"Wang","year":"2025","journal-title":"Cell Rep Med"},{"key":"B27","doi-asserted-by":"publisher","DOI":"10.1038\/s41591-024-02996-7","article-title":"Long-term weight loss effects of semaglutide in obesity without diabetes in the SELECT trial","volume":"30","author":"Ryan","year":"2024","journal-title":"Nat Med"},{"key":"B28","doi-asserted-by":"publisher","DOI":"10.1002\/oby.23374","article-title":"Beyond appetite regulation: targeting energy expenditure, fat oxidation, and lean mass preservation for sustainable weight loss","volume":"30","author":"Christoffersen","year":"2022","journal-title":"Obesity"},{"key":"B29","doi-asserted-by":"publisher","first-page":"788","DOI":"10.1007\/s12325-024-03000-x","article-title":"Glucagon-like peptide-1 receptor agonist-experienced adults with type 2 diabetes switching to once-weekly semaglutide in a real-world setting: SURE program post hoc analysis","volume":"42","author":"Rudofsky","year":"2025","journal-title":"Adv Ther"},{"key":"B30","doi-asserted-by":"publisher","first-page":"43","DOI":"10.1111\/dom.13479","article-title":"Impact on HbA1c and body weight of switching from other GLP\u20101 receptor agonists to semaglutide: a model\u2010based approach","volume":"21","author":"Overgaard","year":"2019","journal-title":"Diabetes Obes Metab"},{"key":"B31","doi-asserted-by":"publisher","DOI":"10.1111\/ijcp.13731","article-title":"Switching between GLP\u20101 receptor agonists in clinical practice: expert consensus and practical guidance","volume":"75","author":"Jain","year":"2021","journal-title":"Int J Clin Pract"},{"key":"B32","doi-asserted-by":"publisher","DOI":"10.3389\/fendo.2024.1349794","article-title":"Female obesity: clinical and psychological assessment toward the best treatment","volume":"15","author":"Guglielmi","year":"2024","journal-title":"Front Endocrinol"},{"key":"B33","doi-asserted-by":"publisher","first-page":"9","DOI":"10.1016\/j.ejim.2025.01.030","article-title":"Bridging the gap: time to integrate sex and gender differences into research and clinical practice for improved health outcomes","volume":"134","author":"Gualtierotti","year":"2025","journal-title":"Eur J Internal Med"},{"key":"B34","doi-asserted-by":"publisher","DOI":"10.3390\/ijms25137342","article-title":"Sex- and gender-related differences in obesity: from pathophysiological mechanisms to clinical implications","volume":"25","author":"Koceva","year":"2024","journal-title":"Int J Mol Sci"},{"key":"B35","doi-asserted-by":"publisher","DOI":"10.3390\/pharmacy13050128","article-title":"Semaglutide in the real world: attitudes of the population","volume":"13","author":"Ru\u0161i\u0107","year":"2025","journal-title":"Pharmacy"},{"key":"B36","doi-asserted-by":"publisher","DOI":"10.1111\/dom.16222","article-title":"Survey among adult users of semaglutide for weight loss in Denmark: user characteristics, treatment expectations and experienced effects","volume":"27","author":"S\u00f8rensen","year":"2025","journal-title":"Diabetes Obes Metab"},{"key":"B37","doi-asserted-by":"publisher","first-page":"103901","DOI":"10.1016\/j.numecd.2025.103901","article-title":"Social, cultural and ethnic determinants of obesity: from pathogenesis to treatment","volume":"35","author":"Capoccia","year":"2025","journal-title":"Nutrition Metab Cardiovasc Dis"},{"key":"B38","doi-asserted-by":"publisher","DOI":"10.1111\/1753-0407.70063","article-title":"Sex differences in the efficacy of glucagon-like peptide-1 receptor agonists for weight reduction: a systematic review and meta-analysis","volume":"17","author":"Yang","year":"2025","journal-title":"J Diabetes"},{"key":"B39","doi-asserted-by":"publisher","DOI":"10.1210\/endocr\/bqae165","article-title":"GLP-1 and its analogs: does sex matter","volume":"166","author":"B\u00f6rchers","year":"2025","journal-title":"Endocrinology"},{"key":"B40","doi-asserted-by":"publisher","DOI":"10.3390\/biomedicines13040855","article-title":"MASLD: prevalence, mechanisms, and sex-based therapies in postmenopausal women","volume":"13","author":"Milani","year":"2025","journal-title":"Biomedicines"},{"key":"B41","doi-asserted-by":"publisher","DOI":"10.1136\/bmjopen-2024-089477","article-title":"Factors associated with weight loss response to GLP-1 analogues for obesity treatment: a retrospective cohort analysis","volume":"15","author":"Squire","year":"2025","journal-title":"BMJ Open"},{"key":"B42","doi-asserted-by":"publisher","DOI":"10.3390\/jcm13123369","article-title":"Sex-differences in response to treatment with liraglutide 3.0 mg","volume":"13","author":"Milani","year":"2024","journal-title":"J Clin Med"},{"key":"B43","doi-asserted-by":"publisher","DOI":"10.1111\/dom.70096","article-title":"Treat to target in weight management with semaglutide: real-world evidence from an eHealth clinic","volume":"27","author":"Seier","year":"2025","journal-title":"Diabetes Obes Metab"},{"key":"B44","doi-asserted-by":"publisher","DOI":"10.1002\/oby.23732","article-title":"Impact of BMI and comorbidities on efficacy of once-weekly semaglutide: post hoc analyses of the STEP 1 randomized trial","volume":"31","author":"McGowan","year":"2023","journal-title":"Obesity"},{"key":"B45","doi-asserted-by":"publisher","DOI":"10.1038\/s41591-023-02526-x","article-title":"Semaglutide in HFpEF across obesity class and by body weight reduction: a prespecified analysis of the STEP-HFpEF trial","volume":"29","author":"Borlaug","year":"2023","journal-title":"Nat Med"},{"key":"B46","doi-asserted-by":"publisher","first-page":"101737","DOI":"10.1016\/j.eclinm.2022.101737","article-title":"Effects of once-weekly semaglutide 2.4 mg on C-reactive protein in adults with overweight or obesity (STEP 1, 2, and 3): exploratory analyses of three randomised, double-blind, placebo-controlled, phase 3 trials","volume":"55","author":"Verma","year":"2023","journal-title":"eClinicalMedicine"},{"key":"B47","doi-asserted-by":"publisher","DOI":"10.57264\/cer-2025-0083","article-title":"Affordable access to GLP-1 obesity medications: strategies to guide market action and policy solutions in the US","volume":"14","author":"Pearson","year":"2025","journal-title":"J Comp Eff Res"},{"key":"B48","doi-asserted-by":"publisher","DOI":"10.3389\/fendo.2024.1382814","article-title":"Semaglutide for weight loss: unanswered questions","volume":"15","author":"Tzoulis","year":"2024","journal-title":"Front Endocrinol"},{"key":"B49","doi-asserted-by":"publisher","DOI":"10.1001\/jamanetworkopen.2024.57349","article-title":"Discontinuation and reinitiation of dual-labeled GLP-1 receptor agonists among US adults with overweight or obesity","volume":"8","author":"Rodriguez","year":"2025","journal-title":"JAMA Netw Open"},{"key":"B50","doi-asserted-by":"publisher","DOI":"10.18553\/jmcp.2025.31.10.1029","article-title":"Patterns and costs associated with glucagon-like peptide-1 receptor agonist use in US adults with type 2 diabetes","volume":"31","author":"Wu","year":"2025","journal-title":"J Manag Care Spec Pharm"},{"key":"B51","doi-asserted-by":"publisher","DOI":"10.1016\/S2213-8587(25)00326-2","article-title":"Obesity legally recognised as a chronic disease in Italy","volume":"13","author":"Bifulco","year":"2025","journal-title":"Lancet Diabetes Endocrinol"}],"container-title":["Frontiers in Endocrinology"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fendo.2026.1819337\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,7,28]],"date-time":"2026-07-28T05:35:24Z","timestamp":1785216924000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fendo.2026.1819337\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,7,28]]},"references-count":51,"alternative-id":["10.3389\/fendo.2026.1819337"],"URL":"https:\/\/doi.org\/10.3389\/fendo.2026.1819337","relation":{},"ISSN":["1664-2392"],"issn-type":[{"value":"1664-2392","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,7,28]]},"article-number":"1819337"}}